Nurix Therapeutics Stock Buy Hold or Sell Recommendation
| NRIX Stock | USD 22.64 0.15 0.66% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Nurix Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Nurix Therapeutics given historical horizon and risk tolerance towards Nurix Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Nurix Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Nurix Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide. In addition, we conduct extensive research on individual companies such as Nurix and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Nurix |
Execute Nurix Therapeutics Buy or Sell Advice
The Nurix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nurix Therapeutics. Macroaxis does not own or have any residual interests in Nurix Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nurix Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Nurix Therapeutics Trading Alerts and Improvement Suggestions
| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia |
Nurix Therapeutics Returns Distribution Density
The distribution of Nurix Therapeutics' historical returns is an attempt to chart the uncertainty of Nurix Therapeutics' future price movements. The chart of the probability distribution of Nurix Therapeutics daily returns describes the distribution of returns around its average expected value. We use Nurix Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nurix Therapeutics returns is essential to provide solid investment advice for Nurix Therapeutics.
| Mean Return | -0.02 | Value At Risk | -4.73 | Potential Upside | 6.17 | Standard Deviation | 3.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nurix Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nurix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Nurix Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Nurix Therapeutics back and forth among themselves.
| Shares | Soleus Capital Management, L.p. | 2024-06-30 | 2.1 M | Geode Capital Management, Llc | 2024-06-30 | 1.3 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 1.2 M | Deutsche Bank Ag | 2024-06-30 | 1 M | Citadel Advisors Llc | 2024-06-30 | 1 M | Nuveen Asset Management, Llc | 2024-06-30 | 981.2 K | Affinity Asset Advisors, Llc | 2024-09-30 | 860.4 K | Blackrock Inc | 2024-06-30 | 6.8 M | Redmile Group, Llc | 2024-09-30 | 4.3 M |
Nurix Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (254.4M) | (102.6M) | 39.4M | 68.3M | 78.5M | 82.5M | |
| Change In Cash | 84.5M | (38.7M) | (15.4M) | (9.8M) | (8.9M) | (8.4M) | |
| Free Cash Flow | (4.6M) | (90.0M) | (172.1M) | (89.8M) | (80.8M) | (84.8M) | |
| Depreciation | 2.2M | 6.1M | 10.8M | 13.7M | 15.7M | 16.5M | |
| Other Non Cash Items | 273K | 1.8M | 636K | (4.9M) | (4.4M) | (4.2M) | |
| Capital Expenditures | 4.6M | 5.7M | 12.2M | 8.4M | 9.7M | 6.3M | |
| Net Income | (43.2M) | (117.2M) | (180.4M) | (143.9M) | (129.6M) | (136.0M) | |
| End Period Cash Flow | 119.5M | 80.8M | 65.4M | 55.5M | 63.9M | 70.0M | |
| Change To Netincome | 401K | 4.6M | 17.6M | 28.3M | 32.6M | 34.2M |
Nurix Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nurix Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nurix Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nurix stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.22 | |
σ | Overall volatility | 3.48 | |
Ir | Information ratio | -0.03 |
Nurix Therapeutics Volatility Alert
Nurix Therapeutics exhibits very low volatility with skewness of -0.74 and kurtosis of 3.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Nurix Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Nurix Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Nurix Therapeutics Fundamentals Vs Peers
Comparing Nurix Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nurix Therapeutics' direct or indirect competition across all of the common fundamentals between Nurix Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nurix Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nurix Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nurix Therapeutics to competition |
| Fundamentals | Nurix Therapeutics | Peer Average |
| Return On Equity | -0.58 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Operating Margin | (4.34) % | (5.51) % |
| Current Valuation | 1.16 B | 16.62 B |
| Shares Outstanding | 70.84 M | 571.82 M |
| Shares Owned By Insiders | 1.45 % | 10.09 % |
| Shares Owned By Institutions | 98.27 % | 39.21 % |
| Number Of Shares Shorted | 9.46 M | 4.71 M |
| Price To Book | 4.20 X | 9.51 X |
| Price To Sales | 28.08 X | 11.42 X |
| Revenue | 76.99 M | 9.43 B |
| Gross Profit | (145.87 M) | 27.38 B |
| EBITDA | (141.41 M) | 3.9 B |
| Net Income | (143.95 M) | 570.98 M |
| Cash And Equivalents | 344.48 M | 2.7 B |
| Cash Per Share | 7.31 X | 5.01 X |
| Total Debt | 30.61 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 5.26 X | 2.16 X |
| Book Value Per Share | 5.62 X | 1.93 K |
| Cash Flow From Operations | (81.36 M) | 971.22 M |
| Short Ratio | 11.33 X | 4.00 X |
| Earnings Per Share | (2.90) X | 3.12 X |
| Target Price | 31.2 | |
| Number Of Employees | 284 | 18.84 K |
| Beta | 2.2 | -0.15 |
| Market Capitalization | 1.58 B | 19.03 B |
| Total Asset | 355.6 M | 29.47 B |
| Retained Earnings | (545.2 M) | 9.33 B |
| Working Capital | 208.54 M | 1.48 B |
| Net Asset | 355.6 M |
Note: Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3 [view details]
Nurix Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nurix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Nurix Therapeutics Buy or Sell Advice
When is the right time to buy or sell Nurix Therapeutics? Buying financial instruments such as Nurix Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nurix Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.